July 29 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON FILES WITH U.S. FDA TO INCLUDE NEW EVIDENCE IN TREMFYA® (GUSELKUMAB) LABEL AS THE ONLY IL-23 INHIBITOR TO DEMONSTRATE SIGNIFICANT INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS